NMNH Capsules: Contract Manufacturing for the Next-Generation NAD+ Precursor

A brand owner reached out to us last year with a frustrating problem: their NMNH capsules were losing potency within 3 months. The label claimed 500mg per serving, but third-party testing showed less than 60% of declared potency remaining. The issue wasn't the raw material — it was the manufacturing environment. NMNH is a reduced molecule, and oxygen exposure during production degrades it rapidly.

We redesigned their production protocol: nitrogen-blanketed mixing, humidity-controlled encapsulation below 40% RH, and immediate sealing after filling. The result: 95%+ potency retention at 18 months.

This is the difference between a factory that has handled NMN for years and one that truly understands what it takes to manufacture NMNH at scale.

What Is NMNH and Why Does It Matter

NMNH (reduced nicotinamide mononucleotide, also called dihydronicotinamide mononucleotide) is the reduced form of NMN. Structurally, it carries one additional hydrogen atom at the C-4 position of the nicotinamide ring — converting the aromatic pyridinium to a non-aromatic 1,4-dihydropyridine.

That single hydrogen changes everything about how the molecule behaves in the body.

The Pathway Difference: Why NMNH Is Not Just "Better NMN"

Most NAD+ precursors — including NMN and NR — are constrained by rate-limiting enzymes. NMN depends on NAMPT (nicotinamide phosphoribosyltransferase). NR depends on NRK (nicotinamide riboside kinase). As people age, the activity of these enzymes declines, which limits how effectively the body can convert these precursors into NAD+.

NMNH takes a completely different route. It is converted directly to NADH by NMNAT (nicotinamide mononucleotide adenylyltransferase) — bypassing both NAMPT and NRK entirely. The resulting NADH is then oxidized to NAD+ by cellular oxidoreductases, including Complex I of the mitochondrial electron transport chain.

This means NMNH does not compete for the same enzymatic bottleneck that limits NMN and NR.

What the Research Shows

Two landmark 2021 publications established NMNH as a distinct and more potent NAD+ precursor:

• Zapata-Pérez et al. (The FASEB Journal, 2021): In mice, a single dose of NMNH produced approximately 5-fold elevation of hepatic NAD+ (compared to approximately 1.5-fold for equimolar NMN). NMNH also significantly elevated NAD+ in the brain, gastrocnemius muscle, brown adipose tissue, and heart — tissues where NMN showed no significant increase.
• Liu et al. (Journal of Proteome Research, 2021): NMNH elevated both NAD+ and NADH in hepatocellular carcinoma cells and mouse liver, with concomitant metabolic reprogramming including suppression of glycolysis and the TCA cycle.

Key pharmacokinetic distinctions reported in preclinical studies:

Human clinical data for NMNH remains limited. An unpublished 90-day trial (reported January 2026) indicated that oral NMNH at 500mg daily approximately tripled circulating NAD+ levels over the treatment period. Formal pharmacokinetic parameters (Cmax, Tmax, AUC) have not yet been published.

Product Specifications

Customization Options

Dosage: 100mg, 250mg, 500mg, 800mg, 1,000mg per capsule — or custom strength per your formula.

Shell: Gelatin, HPMC (plant-based/vegan), or pullulan capsules. All sizes from #00 to #3.

Combination Formulas: We blend NMNH with complementary actives including:

• Resveratrol (trans-resveratrol 98% or 50%)
• PQQ (Pyrroloquinoline Quinone)
• Coenzyme Q10 (CoQ10 / Ubiquinol)
• Quercetin
• Apigenin
• TMG (Trimethylglycine)
• Liposomal delivery systems

Packaging: HDPE bottles, glass bottles, blister packs, pouches — with your private label branding.

Release Format: Immediate-release, sustained-release, or enteric-coated options available.

Why NMNH Manufacturing Is Harder Than NMN — and Why It Matters

This is the section most contract manufacturers won't tell you about.

NMNH is chemically reduced — it carries extra hydrogen. That same property that makes it biologically more potent also makes it far more susceptible to oxidation during manufacturing. Expose NMNH to oxygen and moisture during blending, filling, or encapsulation, and it degrades back toward NMN or breaks down further.

Our NMNH Production Protocol

We developed this protocol across multiple NMNH production runs. The learning curve was real — our first batches showed 8-12% potency loss within 6 months. After iterating on nitrogen flow rates, exposure timing, and packaging configurations, we consistently achieve <3% potency loss at 12 months.

Comparison: NMNH Production Standards

NMNH vs. NMN vs. NR: A Clear Comparison for Brand Positioning

When your customers ask "why NMNH instead of NMN?", you need a clear, defensible answer. Here's the framework we provide to our brand partners:

Important note for brand owners: NMNH is scientifically promising, but human clinical data is still developing. We recommend positioning NMNH products with careful language — focus on "next-generation NAD+ precursor" and "bypasses enzymatic bottlenecks" rather than making efficacy claims that outpace the clinical evidence.

Tiered Product Line Strategy

Based on our experience developing NMNH formulations for global brands, here are three proven tier structures:

Tier 1: NMNH Essential

• NMNH 300mg per serving (2 capsules)
• Target: Entry-level longevity consumers, NMN upgraders
• Positioning: "The next step beyond NMN"
• Price positioning: Mid-range

Tier 2: NMNH Advanced

• NMNH 500mg + trans-Resveratrol 150mg + CoQ10 50mg per serving
• Target: Health-conscious consumers seeking comprehensive NAD+ support
• Positioning: "NAD+ precursor with mitochondrial cofactors"
• Price positioning: Premium

Tier 3: Complete Longevity Stack

• NMNH 800mg + trans-Resveratrol 200mg + PQQ 20mg + Quercetin 150mg + Apigenin 100mg per serving
• Target: Biohackers, longevity enthusiasts, premium wellness brands
• Positioning: "Full-spectrum NAD+ optimization system"
• Price positioning: Ultra-premium

Each tier can be produced in gelatin or vegetarian capsules, with optional liposomal delivery for enhanced bioavailability claims.

Market Context: Where NMNH Fits in 2026

The global NAD+ precursor supplement market is estimated at $876 million (2025), with NMN holding approximately 45% market share. NMNH is emerging as the next-generation alternative, particularly among consumers who have already tried NMN and are looking for something more potent.

Key market drivers:

• NMN regulatory uncertainty: NMN's regulatory status has shifted in multiple markets (FDA review in the US, novel food applications in the EU). NMNH currently occupies a different regulatory position, but brands should monitor evolving guidelines.
• Consumer education: The biohacker community is already discussing NMNH's pathway advantages. As awareness spreads, demand for NMNH products will grow.
• Manufacturing barrier to entry: Because NMNH is harder to produce than NMN, the supplier pool is smaller. This creates a quality gap between experienced manufacturers and newcomers — a gap that directly affects your brand's reputation.

Quality Assurance

Our NMNH manufacturing operates under the same quality management system we apply to all products:

Certifications: ISO9001, ISO22000, FSSC22000, GMP, FDA-registered facility, HALAL, SC, REACH, ECOCERT.

Testing protocol:

• Raw material: Identity (HPLC, MS), purity (≥98%), heavy metals, microbiology, residual solvents
• In-process: Fill weight uniformity, disintegration, moisture content, visual inspection
• Finished product: Potency verification, degradation profiling, microbiology, heavy metals, stability
• Third-party verification: Available upon request (SGS, Eurofins, or your designated lab)

Documentation per batch:

• Certificate of Analysis (COA)
• Batch production record
• Stability data summary
• Material traceability report

Frequently Asked Questions

Q: What is the difference between NMNH and NMN?

A: NMNH is the reduced form of NMN — it carries an additional hydrogen atom. This structural difference means NMNH is converted to NAD+ through a different metabolic pathway that bypasses the rate-limiting enzymes NAMPT and NRK. Preclinical studies show NMNH elevates NAD+ more potently and across more tissues than equimolar NMN, with effects lasting up to 20 hours compared to NMN's ~4 hours. The trade-off is that NMNH is more oxidation-sensitive and harder to manufacture.

Q: Is NMNH safe? What does the safety data show?

A: Published preclinical studies (Liu et al., 2021) tested high-dose NMNH for hepatotoxicity and found no evidence of liver damage. An unpublished 90-day human trial (reported January 2026) at 500mg daily did not report adverse effects. However, comprehensive human safety data is still developing. We recommend that brands include appropriate disclaimers and consult with regulatory advisors for target market compliance.

Q: How do you prevent NMNH from oxidizing during production?

A: We implement a multi-point oxygen control protocol: nitrogen-flushed raw material storage (<40% RH), nitrogen-blanketed closed-system blending, humidity-controlled production (≤45% RH), less than 30 minutes total exposure time from mixing to encapsulation, and immediate desiccant-sealed packaging post-filling. Each batch undergoes potency testing plus degradation product profiling to confirm oxidative stability.

Q: Can NMNH be combined with other ingredients?

A: Yes. We produce NMNH in combination formulas with resveratrol, PQQ, CoQ10, quercetin, apigenin, TMG, and other actives. We also offer liposomal NMNH formulations for brands seeking enhanced bioavailability positioning. Combination formulas require additional stability testing to confirm active-ingredient compatibility.

Q: What is the minimum order quantity?

A: MOQ is 2,000 bottles for standard formulations. Custom combination formulas may require a minimum of 3,000 bottles depending on ingredient sourcing.

Q: What is the production lead time?

A: 3-4 weeks for standard NMNH formulations after formula approval and artwork confirmation. Custom combination formulas or liposomal versions may require 4-5 weeks. Sample production is available within 7-10 business days.

Q: Does NMNH have regulatory approval in the US and EU?

A: NMNH's regulatory status varies by market. In the US, NMNH may qualify as a dietary ingredient under DSHEA, but brands should verify current status with legal counsel. In the EU, NMNH may require novel food authorization. We provide ingredient documentation and regulatory support materials, but final compliance responsibility rests with the brand owner.

Ready to Start Your NMNH Project?

Contact us to discuss your NMNH capsule formulation. We'll provide sample production, stability data, and a detailed manufacturing plan within 48 hours.

Our team responds within 24 hours. MOQ starts at 2,000 bottles. Production lead time: 3-4 weeks.

Related articles:

• Custom Capsule Supplements Manufacturer
• Custom Herbal & Botanical Capsule Supplement Manufacturing
• Mushroom Supplement Capsules Contract Manufacturing
• Vitamin & Mineral Capsule Manufacturing
• Sports & Performance Capsule Manufacturing
• Metabolic, Detox & Weight Management Capsules
• skin care capsule

Related Products：

• Skin Elastin Capsule
• NAD+ Longevity Capsules
• Collagen Capsules